Antimalarial Medications

Dubois' Lupus Erythematosus and Related Syndromes: Eighth Edition

Volumn , Issue , 2013, Pages 601-608

  Aviña Zubieta, J Antonio ^a   Esdaile, John M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942853770     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1893-5.00049-2     Document Type: Chapter

References (74)

1. Wallace DJ The history of antimalarials. Lupus 1996, 5(Suppl 1):S2-S3.
2. Fox RI Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993, 23(2 Suppl 1):82-91.
3. Wallace DJ The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum 1989, 18(4):282-296.
4. Wozniacka A, Lesiak A, Narbutt J, et al. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus 2006, 15(5):268-275.
5. Wozniacka A, Lesiak A, Boncela J, et al. The influence of antimalarial treatment on IL-1β, IL-6 and TNF-α mRNA expression on UVB-irradiated skin in systemic lupus erythematosus. Br J Dermatol 2008, 159(5):1124-1130.
6. Theofilopoulos A, Koundouris S, Kono D, et al. The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res 2001, 3(3):136-141.
7. Wozniacka A, Lesiak A, Narbutt J, et al. Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus. Lupus 2007, 16(2):89-94.
8. Rifkin IR, Leadbetter EA, Busconi L, et al. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005, 204:27-42.
9. Rönnblom L, Alm GV An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 2001, 22(8):427-431.
10. Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Inv 2005, 115(2):407-417.
11. Costedoat-Chalumeau N, Amoura Z, Hulot J-S, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006, 54(10):3284-3290.
12. Lafyatis R, York M, Marshak-Rothstein A Antimalarial agents: closing the gate on Toll-like receptors?. Arthritis Rheum 2006, 54(10):3068-3070.
13. James JA, Kim-Howard XR, Bruner BF, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007, 16(6):401-409.
14. Macfarlane DE, Manzel L Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol 1998, 160(3):1122-1131.
15. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69(1):20-28.
16. Rudnicki RD, Gresham GE, Rothfield NF The efficacy of antimalarials in systemic lupus erythematosus. J Rheumatol 1975, 2(3):323-330.
17. Canadian Hydroxychloroquine Study Group: A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991, 324(3):150-154.
18. Williams HJ, Egger MJ, Singer JZ, et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol 1994, 21(8):1457-1462.
19. Meinão I, Sato E, Andrade L, et al. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 1996, 5(3):237-241.
20. Tsakonas E, Joseph L, Esdaile JM, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998, 7(2):80-85.
21. Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001, 10(6):401-404.
22. Cortes-Hernandez J, Ordi-Ros J, Paredes F, et al. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology 2002, 41(6):643-650.
23. Clowse MEB, Magder L, Witter F, et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006, 54(11):3640-3647.
24. Kasitanon N, Fine DM, Haas M, et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006, 15(6):366-370.
25. Østensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006, 8(3):209.
26. Wallace DJ Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?. Arthritis Rheum 1987, 30(12):1435-1436.
27. Erkan D, Yazici Y, Peterson MG, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology 2002, 41(8):924-929.
28. Toloza SMA, Uribe AG, McGwin G, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004, 50(12):3947-3957.
29. Mok CC, Tang SSK, To CH, et al. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005, 52(9):2774-2782.
30. Ho KT, Ahn CW, Alarcón GS, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology 2005, 44(10):1303-1307.
31. De Leeuw K, Freire B, Smit AJ, et al. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 2006, 15(10):675-682.
32. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006, 15(9):577-583.
33. Mok CC, Tong KH, To CH, et al. Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis: a comparative study. Medicine 2007, 86(4):203-209.
34. Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010, 62(3):863-868.
35. Jancinova V, Nosal R, Petrikova M On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb Res 1994, 74(5):495-504.
36. Rand JH, Wu X-X, Quinn AS, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 2008, 112(5):1687-1695.
37. Rand JH, Wu X-X, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010, 115(11):2292-2299.
38. Wallace DJ, Metzger AL, Stecher VJ, et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990, 89(3):322-326.
39. Rahman P, Gladman DD, Urowitz MB, et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999, 26(2):325-330.
40. Tam LS, Gladman DD, Hallett DC, et al. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000, 27(9):2142-2145.
41. Borba EF, Bonfa E Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 2001, 28(4):780-785.
42. Tanay A, Leibovitz E, Frayman A, et al. Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment. Ann N Y Acad of Sci 2007, 1108:24-34.
43. Petri M Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996, 5(1 Suppl):S16-S22.
44. Penn SK, Kao AH, Schott LL, et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2010, 37(6):1136-1142.
45. Wasko MCM, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007, 298(2):187-193.
46. Rolain J-M, Colson P, Raoult D Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 2007, 30(4):297-308.
47. Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today's diseases. Lancet Infect Dis 2003, 3(11):722-727.
48. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009, 11(4):R109.
49. Sisó A, Ramos-Casals M, Bové A, et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 2008, 17(4):281-288.
50. Bultink IEM, Hamann D, Seelen MA, et al. Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus. Arthritis Res Ther 2006, 8(6):R183.
51. Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005, 52(5):1481-1490.
52. Moss KE, Ioannou Y, Sultan SM, et al. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 2002, 61(5):409-413.
53. Zheng Y, Zhao Y, Deng X, et al. Chloroquine inhibits colon cancer cell growth in vitro and tumor growth in vivo via induction of apoptosis. Cancer Invest 2009, 27(3):286-292.
54. Solomon VR, Lee H Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharm 2009, 625(1-3):220-233.
55. Rahim R, Strobl JS Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs 2009, 20(8):736-745.
56. Ruiz-Irastorza G, Ugarte A, Egurbide MV, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 2007, 66(6):815-817.
57. Sultan SM, Ioannou Y, Isenberg DA Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology 2000, 39(10):1147-1152.
58. Molad Y, Gorshtein A, Wysenbeek AJ, et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 2002, 11(6):356-361.
59. Fessler BJ, Alarcon GS, McGwin G, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005, 52(5):1473-1480.
60. Pons-Estel GJ, Alarcón GS, McGwin G, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Care Res 2009, 61(6):830-839.
61. Ruiz-Irastorza G, Egurbide M-V, Ugalde J, et al. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004, 164(1):77-82.
62. Hernandez-Cruz B, Tapia N, Villa-Romero AR, et al. Risk factors associated with mortality in systemic lupus erythematosus. A case-control study in a tertiary care center in Mexico City. Clin Exp Rheumatol 2001, 19(4):395-401.
63. Alarcon GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007, 66(9):1168-1172.
64. Avina-Zubieta JA, Galindo-Rodriguez G, Newman S, et al. Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis 1998, 57(10):582-587.
65. Easterbrook M The ocular safety of hydroxychloroquine. Sem Arthritis Rheum 1993, 23(2 Suppl 1):62-67.
66. Wolfe F, Marmor MF Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res 2010, 62(6):775-784.
67. Marmor MF, Kellner U, Lai TYY, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011, 118(2):415-422. American Academy of Ophthalmology.
68. Canadian Rheumatology Association Canadian Consensus Conference on hydroxychloroquine. J Rheumatol 2000, 27(12):2919-2921.
69. Wang C, Fortin PR, Li Y, et al. Discontinuation of antimalarial drugs in systemic lupus erythematosus. J Rheumatol 1999, 26(4):808-815.
70. Avina-Zubieta JA, Johnson ES, Suarez-Almazor ME, et al. Incidence of myopathy in patients treated with antimalarials. A report of 3 cases and review of the literature. Rheumatology 1995, 34(2):166-170.
71. Casado E, Gratacós J, Tolosa C, et al. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis 2006, 65(3):385-390.
72. Baguet JP, Tremel F, Fabre M Chloroquine cardiomyopathy with conduction disorders. Heart 1999, 81(2):221-223.
73. Frisk-Holmberg M, Bergkvist Y, Domeij-Nyberg B, et al. Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics. Clin Pharmacol Ther 1979, 25(3):345-350.
74. Thorogood N, Atwal S, Mills W, et al. The risk of antimalarials in patients with renal failure. Post Med J 2007, 83(986):e8.